NantHealth Inc., the Culver City healthcare technology company founded by billionaire Patrick Soon-Shiong, has received Food and Drug Administration approval to market a genetic mapping tool that measures the rate of cell mutations in tumors.
The Nov. 12 announcement marks the first FDA approval of a product that sequences large segments of genes using a method called whole exome sequencing.
In NantHealth’s tool, the sequencing is applied to tumors to determine the rate at which cells mutate and become malignant, which is called the tumor mutation burden. That in turn is used to determine which patients would fare best with immunotherapy treatments for cancer.
According to Soon-Shiong, NantHealth’s chief executive, studies have shown that immunotherapy-treated patients with high rates of cell mutation had better outcomes compared with those with lower mutation rates.
With FDA approval in hand, NantHealth can now take on competitors in the field of mapping genomes to gauge disease risk, including Salt Lake City-based Myriad Genetics Inc. and Burlingame-based Color Genomics Inc.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Deals of the Week: A look at the companies that signed on the dotted line last week
- NantWorks Acquires Precision Biologics
- Soon-Shiong’s NantOmics Acquires Gene Sequencing Startup Genos
- NantHealth Unveils First Product of BlackBerry Collaboration
- Soon-Shiong’s NantHealth Inc. to Support UCSF Breast Cancer Study
- Soon-Shiong’s NantHealth Reports $184 Million Loss
- NantHealth to Market Cancer Diagnostic Test Throughout Southeast Asia
- Soon-Shiong’s NantKwest Launches Clinical Trials for ‘Killer Cells’